The VMIC will be the UK’s first national vaccines manufacturing and innovation facility and aims to respond to pandemics by producing millions of doses quickly.
VMIC has been granted almost £215 million of government funding to date.
In May 2020, the government confirmed additional funding of £93 million to the VMIC - which was first announced in 2018 - to expand and fast track the project. The new £47.6 million is in addition to this funding and will support the delivery of this highly specialist facility during these unprecedented, challenging times.
Through the VMIC, the government also invested £8.75 million in the set-up of a rapid deployment facility at Oxford Biomedica in Oxfordshire, which was a major milestone in increasing UK manufacturing capability of viral vector vaccines.
By October 2020, these 2 additional manufacturing sites were approved by the Medicines and Healthcare Products Regulatory Agency, and are currently producing the Oxford University/AstraZeneca vaccine.